†Some patients were treated with a three-injection Synvisc regimen. A three-injection Synvisc regimen is equivalent to one injection of Synvisc-One.
Synvisc and Synvisc-One are registered trademarks of Genzyme Biosurgery.
Are you looking for a treatment that may allow you to play again?
Are you looking for worry free movement?
Are you looking for pain relief that lasts?
Summary of Indications for Use DUROLANE (3 mL): Symptomatic treatment of mild to moderate knee or hip osteoarthritis. In addition, DUROLANE has been approved in the EU for the symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, shoulder, elbow, wrist, fingers, and toes.
DUROLANE SJ (1 mL): Symptomatic treatment associated with mild to moderate osteoarthritis pain in the ankle, elbow, wrist, fingers, and toes.
Both DUROLANE and DUROLANE SJ are also indicated for pain following joint arthroscopy in the presence of osteoarthritis within 3 months of the procedure.
There are no known contraindications.
You should not use DUROLANE if you have infections or skin disease at the injection site. DUROLANE has not been tested in pregnant or lactating women, or children.
Risks can include transient pain, swelling and/or stiffness at the injection site.
Full prescribing information can be found in product labeling, or at www.durolane.com..
Osteoarthritis: The Ongoing Challenges to Manage Pain
Contact us for additional information